Sai Life Sciences Announces Senior Management Change
Sai Life Sciences Limited announced a change in senior management, effective April 1, 2026. Dr. John Pavey has been appointed as Head - Global PR&D, succeeding Dr. Dean David Edney, who is retiring from the same position at the close of business on March 31, 2026.Dr. Pavey brings over two decades of global experience in CMC and chemical development, previously holding senior leadership roles at Johnson & Johnson, UCB, and AstraZeneca. His expertise encompasses API development across the product lifecycle, regulatory approvals, and commercial supply, with a focus on new modalities, digital chemistry, sustainable manufacturing, and Quality by Design. He holds a BA (Hons) in Chemistry from the University of Oxford, a PhD in Organic Chemistry from the University of Liverpool, and has completed postdoctoral research at the University of Cambridge.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.